Telisotuzumab

DB14838Investigational

Telisotuzumab is under investigation in clinical trial NCT01472016 (Study of ABT-700 in Subjects With Advanced Solid Tumors).

Mechanism: Pharmacologically active on Hepatocyte growth factor receptor
Curator reviewed
Code names: ABT-700

Resolves to

Compound

Clinical / RWD

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Telisotuzumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.